Hypoxic Preconditioning and RGC Protection in Mouse Glau
Principal Investigator
Jeff Gidday, PhD
Louisiana State University Health Sciences Center
New Orleans, LA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
G2006023
Summary
Cells, tissues, organs, and species respond to stress by adaptations that render them more resistant to that same stress. Scientists are now capitalizing on this fundamental response, learning how cells defend themselves when presented with a mild stress, so as to better design therapeutics for true disease. Recently, it was learned that stressing the retina by having mice breath air with a low oxygen content (hypoxia) significantly reduces the death of ganglion cells in the retina when the mice develop experimental glaucoma. These findings imply that genes endogenous to these cells might be activated for glaucoma protection. The present study will focus on heme oxygenase-1, a protein believed to be responsible for the protection of hypoxia-stressed retinal ganglion cells in glaucoma. Dr. Gidday will make extensive determinations of how retinal hypoxia changes the expression of this protein, and will study mice missing or overexpressing this gene to confirm its participation in the protection. Heme oxygenase-1 therapy might represent a new treatment strategy for patients with glaucoma.
Grantee institution at the time of this grant: Washington University
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute